The offering will dilute existing shareholders, likely pressuring the stock near term. Monitor the pricing and actual size; if the offering is completed at a significant discount, further downside is possible. The capital raise suggests cash runway extension but also highlights ongoing cash burn without near-term revenue.
Price Chart
Executive Summary
Intellia Therapeutics announced an underwritten public offering of $150 million in common stock, with an underwriter option for an additional 15%. The offering will dilute existing shareholders and signals a capital need, likely to fund ongoing clinical programs.
Key Financial Metrics
Key Facts
- Intellia commenced an underwritten public offering of $150 million of common stock.
- Underwriters have a 30-day option to purchase up to an additional 15% of the offered shares.
- All shares are being sold by Intellia, resulting in dilution for existing shareholders.
- Jefferies, Goldman Sachs & Co. LLC, and Citigroup are joint book-running managers.
- The offering is subject to market conditions; no assurance on completion or terms.
Financial Impact
Offering size of $150 million, with potential additional 15% ($22.5 million) for total up to $172.5 million. Dilution impact depends on share price at pricing.
Risk Factors
- Dilution from the offering could depress stock price.
- Market conditions may affect completion or terms of the offering.
- No revenue or clinical catalysts mentioned; capital raise may signal delayed milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281994 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers